Member Info for bakky

Ygen do indeed have many strings/products to their bow that is non covid. Just need the ceo to pull his finger out now and sell the stuff! Now where are those big US outfits that will add a bit of jam on top??

I wouldn't pay too much attention to that govt contract figure. Probably only get a fraction of that.

sentiment needs to change. Also, too many small pi sells every time it moves a fraction upwards!!

that contract with NCYT stopped when Ygen brought out their own PCR test named 'Clarigene'.

perhaps a job swap will suffice?

the ending of the surge contract contract was expected. Has it been replaced is another matter. I wouldn't be surprised to see Pcr back on the travel menu soon too.
I would prefer some non covid govt work going forward.

it was expected to end middle of Nov, so what's the problem?

(took a 5 figure loss, but have already recovered 50% of it and expect to break even soon.. yes, famous last words eh? Anyway good luck with that!

read it earlier and yes very impressive how they have adapted so quickly. They just need to find 10/ 15k tests a day going forward for the next year or two. Now that would be impressive!

yes I agree, a lot of confidence needs to be restored after last year. Decent numbers so far and well on the way to hit or even beat numbers for this year. If those US companies are as good as Lyn Rees reckons then it should be very lucrative going forward.

how do they plug the covid revenue loss going forward? Second half covid income will be much lower as we know. Heaven knows when the US stuff will kick in with decent numbers. They need more govt contracts, but it looks like they missed out on those 3 'live' ones LR mentioned.

BMD is a pump and dump merchant, BEWARE!!

Your last sentence must be the understatement of the year so far. lol

from adv, c/o rivaldo, apologies if already posted!

Interesting from Finncap's updated research note today - Nutrition and CD4 cover the current m/cap, so Covid is essentially in the price for free at present:

"Forecasts and valuation.

With the DHSC yet to decide which lateral flow antigen test Omega Diagnostics will manufacture, the company understandably is giving no guidance, given the potential magnitude of such orders. However, this initial order and the potential to extend the agreement to include VISITECT antigen self-test LFT, once CE marked, as well as Food Detective points to substantial revenue growth in FY 2022. We leave our FY 2022 forecasts and target price under review, arguing that Health & Nutrition and VISITECT CD4 underpin the current c.£90m valuation – with COVID-19 providing the substantial potential upside."

Lyn, oh you naughty naughty boy winding up the village idiot like that..lol Just fills my screen with green boxes which I suppose is funny!

Coop, doing exactly that. could kick off around 5th/8th Nov, well according to my lad anyway..lol

RYN, why do you bother replying ? Green box is sooooo much better!

If they can't make any profit out of this lot by y/e then LR needs to examine his business model, cos it doesn't work. Hopefully Asia can make a much better contribution from here on in. Not sure just when the US is going to make good contributions though. Seems never ending waiting for those blue chips to pop out and be known. This Ranger tech looks good too.Could be a good money spinner.

C'mon Lyn, we need some new contracts pdq. I thought one of their new US ventures kicked off in Oct this year? Was hoping to hear something from that.

Nice £1m saving with a bit of reorganisation too this year. Maybe getting rid of a few hangers on at board level? All helps the cause.